BMS Sep 1, 2022 Multiple Myeloma Researchers Chip Away at Why Some Patients Relapse Quickly After CAR T-Cell Therapy Premium Aug 26, 2022 Melanoma Docs Resurrect PD-L1 Debate as CHMP, FDA Diverge on Opdualag Label Premium Aug 19, 2022 In Brief This Week: Genprex, Strata Oncology, Bristol Myers Squibb, Turning Point Therapeutics Aug 17, 2022 Tessa Therapeutics Starts Trial of CAR T-Cell Therapy, BMS's Opdivo in Classical Hodgkin Lymphoma Aug 10, 2022 Bristol Myers Squibb, 2seventy Bio Eyeing Earlier-Line Multiple Myeloma Abecma Indication Jul 28, 2022 Turning Point Therapeutics Receives Positive FDA Feedback on Repotrectinib NSCLC Application Jul 27, 2022 BMS Reports Q2 Growth in CAR T-Cell Therapies Despite Manufacturing Hurdles Premium Jul 22, 2022 Bristol Myers Squibb's Opdualag Gets EMA CHMP Recommendation for Biomarker-Selected Melanoma Jul 12, 2022 NCCN Publishes First Guidelines for Pediatric Brain Cancer, Recommends Broad NGS Profiling Jun 28, 2022 European Commission Approves Gilead Sciences' Yescarta for Follicular Lymphoma Patients Jun 27, 2022 FDA Approves Bristol Myers Squibb's Breyanzi for Second-Line Lymphoma Patients Jun 20, 2022 BMS Submits Breyanzi for European Approval as Second-Line Lymphoma Treatment Jun 4, 2022 At ASCO, Biomarker Strategies Show Potential for Guiding Metastatic Pancreatic Cancer Treatment Premium May 31, 2022 Novartis' Kymriah Nabs FDA Approval in Refractory Follicular Lymphoma May 27, 2022 BMS Shows Breyanzi Benefit in Stem Cell Transplant-Ineligible LBCL May 16, 2022 BMS's Opdivo, Yervoy Combo Fails to Improve Overall Survival Versus Chemo in Bladder Cancer Trial May 12, 2022 Bristol Myers Squibb Scoops Up Rights to BridgeBio's SHP2 Inhibitor May 10, 2022 Immatics Begins Phase I Trial of T-Cell Receptor Bispecific IMA401 in Advanced Solid Tumors May 6, 2022 Drugmakers Come Together Hoping to Formalize MRD as Surrogate Endpoint in AML Trials May 5, 2022 BMS, Merck KGaA Partner with Amphista Therapeutics to Develop Targeted Protein Degraders Load More Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week:Â Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
